{
  "id": 16627632,
  "title": "BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study",
  "url": "https://urgent.news/2026/10/26/biontech-dualitybio-say-adc-had-modest-benefit-in-breast-cancer-study",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T16:06:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/biontech-dualitybio-modest-results-adc-breast-cancer/839574/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}